<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05008939</url>
  </required_header>
  <id_info>
    <org_study_id>ShanghaiFMIH2021 Zhiqiang Liu</org_study_id>
    <nct_id>NCT05008939</nct_id>
  </id_info>
  <brief_title>Sevoflurane for Treatment-Resistant Depression</brief_title>
  <official_title>Subanesthetic Sevoflurane for Treatment-Resistant Depression: A Proof-of-Concept Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai First Maternity and Infant Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Pudong New Area Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai First Maternity and Infant Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intends to carry out a prospective, randomized, double-blind, placebo-controlled&#xD;
      study to evaluate the efficacy and safety of subanesthetic sevoflurane for&#xD;
      treatment-resistant depression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of treatment responses in 17-item Hamilton Depression Rating Scale (HDRS-17)</measure>
    <time_frame>24 hours after the end of treatment</time_frame>
    <description>≥50% HDRS-17 reduction in depressive symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of treatment responses in HDRS-17</measure>
    <time_frame>2 hours, 7 days,14 days and 28 days after the end of treatment</time_frame>
    <description>≥50% HDRS-17 reduction in depressive symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of remissions in HDRS-17</measure>
    <time_frame>2 hours, 24 hours, 7 days,14 days and 28 days after the end of treatment</time_frame>
    <description>HDRS-17 ≤7 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of treatment responses in Montgomery-Åsberg Depression Rating Scale (MADRS)</measure>
    <time_frame>2 hours, 24 hours, 7 days,14 days and 28 days after the end of treatment</time_frame>
    <description>≥50% MADRS reduction in the baseline score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of remissions in MADRS</measure>
    <time_frame>2 hours, 24 hours, 7 days,14 days and 28 days after the end of treatment</time_frame>
    <description>MADRS &lt;10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The assessment of depression with self-rating scale</measure>
    <time_frame>2 hours, 24 hours, 7 days,14 days and 28 days after the end of treatment</time_frame>
    <description>The changes of score in Patient Health Questionnaire-9 (PHQ-9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The assessment of anxiety by psychiatrist</measure>
    <time_frame>2 hours, 24 hours, 7 days,14 days and 28 days after the end of treatment</time_frame>
    <description>The changes of score in Hamilton Anxiety Rating Scale (HAMA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The assessment of anxiety with self-rating scale</measure>
    <time_frame>2 hours, 24 hours, 7 days,14 days and 28 days after the end of treatment</time_frame>
    <description>The changes of score in Generalized Anxiety Disorder Screener (GAD-7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The assessment of improvement by psychiatrist</measure>
    <time_frame>2 hours, 24 hours, 7 days,14 days and 28 days after the end of treatment</time_frame>
    <description>The changes of score in Clinical Global Impression (CGI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The assessment of improvement with self-rating scale</measure>
    <time_frame>2 hours, 24 hours, 7 days,14 days and 28 days after the end of treatment</time_frame>
    <description>The changes of score in Patient Global Impressions of Improvement (PGI-I)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The assessment of side effects with self-rating scale</measure>
    <time_frame>2 hours, 24 hours, 7 days,14 days and 28 days after the end of treatment</time_frame>
    <description>Including Patient Rated Inventory of Side Effects (PRISE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects of sevoflurane</measure>
    <time_frame>up to 2 hours after the end of treatment</time_frame>
    <description>Including nausea, vomiting, headache, dizzy, hypotension, hypoxemia, carbon dioxide accumulation, et al</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Depressive Disorder, Treatment-Resistant</condition>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>sevoflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Those with 1-hour inhalation of 1% sevoflurane/30% oxygen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Those with 1-hour inhalation of 30% oxygen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Patients receive 1% sevoflurane and 30% oxygen for 1 hour.</description>
    <arm_group_label>sevoflurane</arm_group_label>
    <other_name>Treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients received 30% oxygen for 1 hour.</description>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_label>sevoflurane</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age 18-65 years&#xD;
&#xD;
          2. meeting DSM-V criteria for major depressive disorder&#xD;
&#xD;
          3. a pretreatment score ≥17 on HDRS-17&#xD;
&#xD;
          4. meeting criteria for TRD, defined as having had at least two adequate dose-duration&#xD;
             antidepressant medication failures in the current depressive episode.&#xD;
&#xD;
          5. current treatment drugs were stably used for at least 4 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. MDD with psychosis, e.g., bipolar disorder, schizophrenia, schizoaffective disorder,&#xD;
             obsessive-compulsive disorder, panic disorder, et al&#xD;
&#xD;
          2. Drug, tobacco or alcohol abuse&#xD;
&#xD;
          3. active suicidal intention&#xD;
&#xD;
          4. previous administration of NMDA receptor antagonists (e.g., ketamine)&#xD;
&#xD;
          5. previous (&lt;6 weeks prior) or ongoing treatment with electroconvulsive therapy (ECT) or&#xD;
             transcranial magnetic stimulation (TMS)&#xD;
&#xD;
          6. pregnancy or breastfeeding&#xD;
&#xD;
          7. morbidly obese, BMI&gt;35kg/m2&#xD;
&#xD;
          8. other diseases that could interfere with the results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhiqiang Liu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anesthesiaology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fuyi Shen, MD</last_name>
    <phone>86-13524123072</phone>
    <email>shenfuyi315@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhiqiang Liu, MD</last_name>
    <phone>86-13816877756</phone>
    <email>drliuzhiqiang@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>02148</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Fuyi Shen, MD</last_name>
      <phone>86-13524123072</phone>
      <email>shenfuyi315@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhiqiang Liu, MD</last_name>
      <phone>86-13816877756</phone>
      <email>drliuzhiqiang@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 2009 Nov;60(11):1439-45. doi: 10.1176/ps.2009.60.11.1439.</citation>
    <PMID>19880458</PMID>
  </reference>
  <reference>
    <citation>Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006 Jan;163(1):28-40.</citation>
    <PMID>16390886</PMID>
  </reference>
  <reference>
    <citation>Mrazek DA, Hornberger JC, Altar CA, Degtiar I. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013. Psychiatr Serv. 2014 Aug 1;65(8):977-87. doi: 10.1176/appi.ps.201300059. Review.</citation>
    <PMID>24789696</PMID>
  </reference>
  <reference>
    <citation>Papakostas GI, Petersen TJ, Farabaugh AH, Murakami JL, Pava JA, Alpert JE, Fava M, Nierenberg AA. Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder. J Clin Psychiatry. 2003 Nov;64(11):1357-61.</citation>
    <PMID>14658951</PMID>
  </reference>
  <reference>
    <citation>Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS; Scientific Advisory Board and the Executive Committee of the Grand Challenges on Global Mental Health, Anderson W, Dhansay MA, Phillips A, Shurin S, Walport M, Ewart W, Savill SJ, Bordin IA, Costello EJ, Durkin M, Fairburn C, Glass RI, Hall W, Huang Y, Hyman SE, Jamison K, Kaaya S, Kapur S, Kleinman A, Ogunniyi A, Otero-Ojeda A, Poo MM, Ravindranath V, Sahakian BJ, Saxena S, Singer PA, Stein DJ. Grand challenges in global mental health. Nature. 2011 Jul 6;475(7354):27-30. doi: 10.1038/475027a.</citation>
    <PMID>21734685</PMID>
  </reference>
  <reference>
    <citation>Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry. 2007 Jan;52(1):46-54. Review.</citation>
    <PMID>17444078</PMID>
  </reference>
  <reference>
    <citation>Sanacora G, Schatzberg AF. Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology. 2015 Mar 13;40(5):1307. doi: 10.1038/npp.2014.338.</citation>
    <PMID>25767082</PMID>
  </reference>
  <reference>
    <citation>Chen C, Ji M, Xu Q, Zhang Y, Sun Q, Liu J, Zhu S, Li W. Sevoflurane attenuates stress-enhanced fear learning by regulating hippocampal BDNF expression and Akt/GSK-3β signaling pathway in a rat model of post-traumatic stress disorder. J Anesth. 2015 Aug;29(4):600-8. doi: 10.1007/s00540-014-1964-x. Epub 2014 Dec 23.</citation>
    <PMID>25533726</PMID>
  </reference>
  <reference>
    <citation>Zhang H, Li L, Sun Y, Zhang X, Zhang Y, Xu S, Zhao P, Liu T. Sevoflurane prevents stroke-induced depressive and anxiety behaviors by promoting cannabinoid receptor subtype I-dependent interaction between β-arrestin 2 and extracellular signal-regulated kinases 1/2 in the rat hippocampus. J Neurochem. 2016 May;137(4):618-29. doi: 10.1111/jnc.13613. Epub 2016 Mar 31.</citation>
    <PMID>26991409</PMID>
  </reference>
  <reference>
    <citation>Luo C, Zhang YL, Luo W, Zhou FH, Li CQ, Xu JM, Dai RP. Differential effects of general anesthetics on anxiety-like behavior in formalin-induced pain: involvement of ERK activation in the anterior cingulate cortex. Psychopharmacology (Berl). 2015 Dec;232(24):4433-44. doi: 10.1007/s00213-015-4071-2. Epub 2015 Sep 24.</citation>
    <PMID>26400403</PMID>
  </reference>
  <reference>
    <citation>Guo Z, Zhao F, Wang Y, Wang Y, Geng M, Zhang Y, Ma Q, Xu X. Sevoflurane Exerts an Anti-depressive Action by Blocking the HMGB1/TLR4 Pathway in Unpredictable Chronic Mild Stress Rats. J Mol Neurosci. 2019 Dec;69(4):546-556. doi: 10.1007/s12031-019-01380-2. Epub 2019 Jul 31.</citation>
    <PMID>31368063</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>treatment-resistant depression (TRD)</keyword>
  <keyword>major depressive disorder (MDD)</keyword>
  <keyword>sevoflurane</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

